Hiroi Clinic: Low-Dose Opdivo Immunotherapy & Clinical Evidence

Located in Fukuoka, Japan, Hiroi Clinic is an advanced cancer immunotherapy institution founded by Director Hiroi. With a deep background in "acute care" and "oncology," Director Hiroi provides an innovative path for cancer patients different from conventional chemotherapy.

Core Technology: Precise Immune Checkpoint Inhibition

Hiroi Clinic specializes in the use of Immune Checkpoint Inhibitors, which work by releasing the immune suppression of T cells, allowing them to re-recognize and attack cancer cells:

• Low-Dose Strategy: The clinic routinely uses approximately 20mg of Opdivo (standard dose is 240mg) and 10mg of Yervoy. This strategy aims to trigger an immune response with minimal medication while minimizing immune-related side effects (such as interstitial pneumonia, myositis, etc.).
• Combination Therapy (Opdivo + Yervoy): By simultaneously blocking two different immune switches, PD-1 and CTLA-4, it further enhances T cell activation and proliferation to combat refractory or progressive cancers.

Applicable Conditions and Experience

Director Hiroi has accumulated clinical data from over 150 advanced cancer patients. The clinic has extensive experience and records in treating the following conditions:

• Unresectable progressive or recurrent non-small cell lung cancer.
• Colorectal cancer with MSI-High characteristics.
• Gastric cancer, esophageal cancer, and pleural mesothelioma that have worsened after chemotherapy.

Medical Consultant's Review

The advantage of Hiroi Clinic lies in its "human-centered" dose adjustment. For patients who are physically weak or have low tolerance for conventional chemotherapy side effects, Director Hiroi's low-dose regimen provides an option to maintain dignity and quality of life. Its location in Fukuoka also offers great convenience for patients from other Asian regions.

【Medical Supporter Compliance Statement】 Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).